Approxima, an innovative early-stage MedTech startup based in Milan, Italy, is excited to announce the successful completion of a funding round, securing €1,600,000 to advance its groundbreaking medical technology. The company is at the forefront of revolutionizing cardiac care, focused on developing a pioneering percutaneous tricuspid valve repair system. This cutting-edge approach employs right ventricular reshaping to effectively treat tricuspid regurgitation, a condition affecting a significant number of patients worldwide. The newly raised capital will be instrumental in propelling the company’s preclinical feasibility phase studies, crucial milestones aimed at demonstrating the in-vivo feasibility, efficacy, and safety of the proposed system.
With this funding, Approxima intends to accelerate its research and development efforts, bringing forth the much-needed innovation in the treatment of tricuspid regurgitation - a condition often overlooked in the realm of cardiac ailments. The startup’s dedicated team of engineers and medical professionals is committed to developing solutions that not only enhance patient outcomes but also improve quality of life. By harnessing advanced technology and collaborating with leading experts in the field, Approxima is positioning itself as a frontrunner in the MedTech landscape. This significant funding round marks an exciting milestone for the company as it strives to transform cardiac care and offer impactful solutions for patients suffering from this chronic condition. As Approxima continues to forge ahead, the support of its investors will play a vital role in realizing its vision of a healthier future through innovative medical interventions.
